Related Experiment Video
Updated: Dec 16, 2025
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.0K
Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression
Konghe Hu1, Wenquan Xie1, Songjia Ni2
1Department of Spine Surgery, The Affiliated Yuebei People's Hospital of Shantou University Medical College, Shaoguan, Guangdong 512025, P.R. China.
Oncology Reports
|July 7, 2020
Summary
Cadmium chloride may improve osteosarcoma treatment by increasing sensitivity to cisplatin. This effect is linked to the downregulation of forkhead box protein M1 (FOXM1), suggesting FOXM1 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma is a malignant bone cancer with poor prognosis.
- Chemotherapeutic response is critical for patient outcomes.
- The role of heavy metals like cadmium in osteosarcoma treatment is unexplored.
Purpose of the Study:
- To investigate the effects of cadmium chloride on osteosarcoma cells.
- To determine the role of forkhead box protein M1 (FOXM1) in cadmium-induced chemosensitivity.
- To evaluate cadmium chloride as a potential adjuvant therapy for osteosarcoma.
Main Methods:
- Treatment of MG63 osteosarcoma cells with cadmium chloride.
- Gene expression profiling using GeneChip technology.
- Lentiviral-mediated silencing of FOXM1 in cells and in vivo studies using nude mice.
Main Results:
- Cadmium chloride downregulated FOXM1 expression in osteosarcoma cells.
- Silencing FOXM1 confirmed its role in cisplatin resistance.
- Cadmium chloride enhanced osteosarcoma sensitivity to cisplatin in vivo, mediated by FOXM1.
Conclusions:
- Cadmium chloride alters osteosarcoma sensitivity to cisplatin via FOXM1.
- FOXM1 is a potential therapeutic target and prognostic factor for osteosarcoma.
- Cadmium chloride shows promise as an adjuvant therapy to enhance cisplatin efficacy.
